Molecular determinants of resistance to antiandrogen therapy
The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
Using microarray-based profiling of isogenic prostate cancer xenograft models, we found that a modest increase in androgen receptor mRNA was the only change consistently associated with the development of resistance to antiandrogen therapy. This increase in androgen receptor mRNA and protein was both necessary and sufficient to convert prostate cancer growth from a hormone-sensitive to a hormone-refractory stage, and was dependent on a functional ligand-binding domain. Androgen receptor antagonists showed agonistic activity in cells with increased androgen receptor levels; this antagonist-agonist conversion was associated with alterations in the recruitment of coactivators and corepressors to the promoters of androgen receptor target genes. Increased levels of androgen receptor confer resistance to antiandrogens by amplifying signal output from low levels of residual ligand, and by altering the normal response to antagonists. These findings provide insight toward the design of new antiandrogens.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“FKBP51 overexpression was not detected in a previous microarray analysis of the LAPC-4 xenografts (3).”
From FKBP51 Promotes Assembly of the Hsp90 Chaperone Complex and Regulates Androgen Receptor Signaling in Prostate Cancer Cells (2010) · cites this paper as [3]
In the citing paper
“which is known to promote AI-type growth in human prostate cancer models (3)”
From FKBP51 Promotes Assembly of the Hsp90 Chaperone Complex and Regulates Androgen Receptor Signaling in Prostate Cancer Cells (2010) · cites this paper as [3]
In the citing paper
“AR overexpression is a signature of AI disease, and forcing AR expression in model systems is sufficient to generate AI growth and responsiveness to antiandrogens (3).”
From FKBP51 Promotes Assembly of the Hsp90 Chaperone Complex and Regulates Androgen Receptor Signaling in Prostate Cancer Cells (2010) · cites this paper as [3]
In the citing paper
“AR overexpression is a signature of AI disease, and forcing AR expression in model systems is sufficient to generate AI growth and responsiveness to antiandrogens (3).”
From FKBP51 Promotes Assembly of the Hsp90 Chaperone Complex and Regulates Androgen Receptor Signaling in Prostate Cancer Cells (2010) · cites this paper as [3]
In the citing paper
“Several studies have provided evidence that this disease progression may be due in part to intratumoral synthesis of androgens, with castration-resistant prostate-cancer cells overexpressing the enzymes required for androgen biosynthesis.”
From Abiraterone and Increased Survival in Metastatic Prostate Cancer (2011) · cites this paper as [35]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Molecular portraits of human breast tumours
Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,261 · cited 1×
“Because xenograft-specific expression signatures are likely to obscure the gene expression changes responsible for the transition from hormone-sensitive to hormone-refractory state”
BackgroundShiau, A. K., Barstad, D., Loria, P. M., Cheng, L., Kushner, P. J., Agard, D. A., & Greene, G. L. (1998) · Cell · doi:10.1016/s0092-8674(00)81717-1 · Cited by 2,729 · cited 1×
“Because steroid receptor–antagonist complexes adopt a variety of conformation”
BackgroundThe development of androgen-independent prostate cancer.
Feldman, B. J., & Feldman, D. (2001) · Nature reviews. Cancer · doi:10.1038/35094009 · Cited by 2,326 · cited 1×
“The postulated mechanisms to explain resistance to hormone therapy can be separated into three general categorie”
BackgroundThe coregulator exchange in transcriptional functions of nuclear receptors
Glass, C. K., & Rosenfeld, M. G. (2000) · Genes & Development · doi:10.1101/gad.14.2.121 · Cited by 2,233
Self-citationActivation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase
Kato, S., Endoh, H., Masuhiro, Y., Kitamoto, T., Uchiyama, S., Sasaki, H., Masushige, S., Gotoh, Y., Nishida, E., Kawashima, H., et al. (1995) · Science · doi:10.1126/science.270.5241.1491 · Cited by 1,964 · cited 1×
“The kinases and substrates responsible for androgen receptor activation in this setting are unknown, but it is presumed to occur through downstream phosphorylation of androgen receptor–associated proteins or through the androgen receptor itself, analogous to the estrogen recepto”
BackgroundLNCaP model of human prostatic carcinoma.
Horoszewicz, J. S., Leong, S. S., Kawinski, E., Karr, J. P., Rosenthal, H. E., Chu, T. M., MIRAND, E. A., & Murphy, G. P. (1983) · PubMed · Cited by 1,789
In vivo amplification of the androgen receptor gene and progression of human prostate cancer
Visakorpi, T., Hyytinen, E., Koivisto, P., Tanner, M., Keinänen, R., Palmberg, C., Palotie, A., Tammela, T., Isola, J., & Kallioniemi, O.-P. (1995) · Nature Genetics · doi:10.1038/ng0495-401 · Cited by 1,484
Mutation of the Androgen-Receptor Gene in Metastatic Androgen-Independent Prostate Cancer
Taplin, M.-E., Bubley, G. J., Shuster, T. D., Frantz, M. E., Spooner, A. E., Ogata, G. K., Keer, H. N., & Balk, S. P. (1995) · New England Journal of Medicine · doi:10.1056/nejm199505253322101 · Cited by 1,253
Molecular Determinants for the Tissue Specificity of SERMs
Shang, Y., & Brown, M. (2002) · Science · doi:10.1126/science.1068537 · Cited by 1,146 · cited 1×
“Previous work has shown that the agonist-versus-antagonist response of nuclear receptors, such as the estrogen receptor, is altered by increased expression of coactivators (such as SRC-1) or by decreased expression of corepressors (such as NCoR”
BackgroundNongenotropic, Sex-Nonspecific Signaling through the Estrogen or Androgen Receptors
Kousteni, S., Bellido, T., Plotkin, L. I., O'Brien, C. A., Bodenner, D. L., Han, L., Han, K., DiGregorio, G. B., Katzenellenbogen, J. A., Katzenellenbogen, B. S., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00268-9 · Cited by 1,113
Cited by
Items 101–200 of 1,002
Miyamoto, D. T., Lee, R. J., Stott, S. L., Ting, D. T., Wittner, B. S., Ulman, M., Smas, M. E., Lord, J. B., Brannigan, B. W., Trautwein, J., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0222 · Cited by 272
Systematic Analysis of MicroRNAs Targeting the Androgen Receptor in Prostate Cancer Cells
Östling, P., Leivonen, S.-K., Aakula, A., Kohonen, P., Mäkelä, R., Hagman, Z., Edsjö, A., Kangaspeska, S., Edgren, H., Nicorici, D., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2421 · Cited by 270
“sensitive to a hormone-refractory state (6).”
BackgroundJung, M. E., Ouk, S., Yoo, D., Sawyers, C. L., Chen, C., Tran, C., & Wongvipat, J. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901488g · Cited by 266
Self-citationRathkopf, D. E., Morris, M. J., Fox, J. J., Danila, D. C., Slovin, S. F., Hager, J. H., Rix, P. J., Chow Maneval, E., Chen, I., Gönen, M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.1684 · Cited by 261
Self-citationAn, J., Wang, C., Deng, Y., Yu, L., & Huang, H. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.01.013 · Cited by 260
“…pathways; overexpression of AR coactivators; intracrine signaling by increased intratumoral androgen synthesis; and expression of constitutively active splicing variants of AR (Cai et al., 2011; Chen et al., 2004; Dehm and Tindall, 2011; Grossmann et al., 2001; Scher and Sawyers, 2005).”
BackgroundInfluentialNew androgen receptor genomic targets show an interaction with the ETS1 transcription factor
Massie, C. E., Adryan, B., Barbosa‐Morais, N. L., Lynch, A. G., Tran, M. G., Neal, D. E., & Mills, I. G. (2007) · The EMBO Reports · doi:10.1038/sj.embor.7401046 · Cited by 259
“EMBO open New androgen receptor genomic targets show an interaction with the ETS1 transcription factor”
BackgroundZhu, P., Baek, S. H., Bourk, E. M., Ohgi, K. A., Garcia-Bassets, I., Sanjo, H., Akira, S., Kotol, P. F., Glass, C. K., Rosenfeld, M. G., et al. (2006) · Cell · doi:10.1016/j.cell.2005.12.032 · Cited by 259
“These compounds typically function initially as antagonists in vivo but almost invariably become ineffective over a period of time (Feldman and Feldman, 2001; Chen et al., 2004; reviewed in Debes and Tindall, 2004).”
InfluentialSelf-citationA Convergence-Based Framework for Cancer Drug Resistance
Konieczkowski, D. J., Johannessen, C. M., & Garraway, L. A. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.025 · Cited by 258
“In prostate cancer, for example, where signaling through the androgen receptor (AR) is central to oncogenesis (Figure 3B), the efficacy of AR-directed therapeutics can be thwarted by AR mutation (Taplin et al., 1995), amplification (Visakorpi et al., 1995), or overexpression (Chen et al., 2004).”
Chmelar, R., Buchanan, G., Need, E. F., Tilley, W., & Greenberg, N. M. (2007) · International Journal of Cancer · doi:10.1002/ijc.22365 · Cited by 255
“Alterations in cofactor levels and function have been proposed to contribute to the emergence of ADI disease.(15) Immunohistochemical evaluation of the three p160 coactivators in benign and cancerous prostate tissues demonstrated over expression of SRC1 in approximately half of prostate tumors grown in an intact andro…”
BackgroundPeptidomimetic targeting of critical androgen receptor–coregulator interactions in prostate cancer
Ravindranathan, P., Lee, T.-K., Yang, L., Centenera, M. M., Butler, L., Tilley, W. D., Hsieh, J.-T., Ahn, J.-M., & Raj, G. V. (2013) · Nature Communications · doi:10.1038/ncomms2912 · Cited by 257
Schweizer, M. T., Antonarakis, E. S., Wang, H., Ajiboye, A. S., Spitz, A., Cao, H., Luo, J., Haffner, M. C., Yegnasubramanian, S., Carducci, M. A., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.3010563 · Cited by 254
“demonstrated that prostate cancer cell lines adapt to serial passage in castrated mice through anautoregulatory increase inARexpression that is sufficient to induce resistance tobothADTand the antiandrogen bicalutamide (25).”
BackgroundTargeting cytochrome P450 enzymes: A new approach in anti-cancer drug development
Bruno, R. D., & Njar, V. C. O. (2007) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2007.05.046 · Cited by 249
Androgen Receptor Splice Variants Determine Taxane Sensitivity in Prostate Cancer
Thadani-Mulero, M., Portella, L., Sun, S., Sung, M., Matov, A., Vessella, R. L., Corey, E., Nanus, D. M., Plymate, S. R., & Giannakakou, P. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2876 · Cited by 256
“In fact, despite androgen ablation, the progression to castration-resistant prostate cancer (CRPC) remains androgen receptor driven (4) because of several mechanisms, including androgen receptor gene amplification, in situ androgen production (5), the presence of ligand-independent androgen receptor splice variants th…”
Self-citationAndrogen Receptor Structural and Functional Elements: Role and Regulation in Prostate Cancer
Dehm, S. M., & Tindall, D. J. (2007) · Molecular Endocrinology · doi:10.1210/me.2007-0223 · Cited by 253
Castration-resistant Prostate Cancer: From New Pathophysiology to New Treatment Targets
Chi, K. N., Bjartell, A., Dearnaley, D., Saad, F., Schröder, F. H., Sternberg, C., Tombal, B., & Visakorpi, T. (2009) · European Urology · doi:10.1016/j.eururo.2009.06.027 · Cited by 253
“High AR levels were also associated with a change in the effect of bicalutamide from an AR antagonist to agonist [15], providing a further mechanism for antiandrogen withdrawal effects observed in the clinic.”
BackgroundInfluentialMosquera, J. M., Beltran, H., Park, K., MacDonald, T. Y., Robinson, B. D., Tagawa, S. T., Perner, S., Bismar, T. A., Erbersdobler, A., Dhir, R., et al. (2013) · Neoplasia · doi:10.1593/neo.121550 · Cited by 249
“Alternative mechanisms of resistance also include up-regulation or continued activation of the AR [28].”
BackgroundXu, K., Shimelis, H., Linn, D. E., Jiang, R., Yang, X., Sun, F., Guo, Z., Chen, H., Li, W., Chen, H., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.02.021 · Cited by 248
“It is well accepted that AR plays an important role in development of prostate cancer as well as progression to androgen-independent disease (Chen et al., 2004; Zegarra-Moro et al., 2002).”
BackgroundAndrogen Receptor Rediscovered: The New Biology and Targeting the Androgen Receptor Therapeutically
Ryan, C. J., & Tindall, D. J. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.2005 · Cited by 244
“Chen and Sawyers demonstrated a relationship between AR overexpression and the capability of androgen independent growth, suggesting that this relationship is one shaped by a misallocation in the balance between AR co-activators and co-repressors due to high levels of the receptor [31].”
BackgroundSteroid Hormone Receptors in Prostate Cancer: A Hard Habit to Break?
Attard, G., Cooper, C. S., & de Bono, J. S. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.11.006 · Cited by 242
“An increase in AR mRNA expression is sufficient in vitro to convert the action of bicalutamide from an overall AR antagonist to an agonist (Chen et al., 2004).”
BackgroundThe deficiency of Akt1 is sufficient to suppress tumor development in Pten +/− mice
Chen, M.-L., Xu, P.-Z., Peng, X., Chen, W. S., Guzman, G., Yang, X., Di Cristofano, A., Pandolfi, P. P., & Hay, N. (2006) · Genes & Development · doi:10.1101/gad.1395006 · Cited by 241
“…in light of the recent observation that elevated AR expression in human prostate tumors correlates with increased resistance to AR antagonists (Chen et al. 2004), these observations imply that prostate tumors in which Akt is activated may be more resistant to hormone therapy and that…”
BackgroundAndrogen Receptor Variants Occur Frequently in Castration Resistant Prostate Cancer Metastases
Zhang, X., Morrissey, C., Sun, S., Ketchandji, M., Nelson, P. S., True, L. D., Vakar-Lopez, F., Vessella, R. L., & Plymate, S. R. (2011) · PLoS ONE · doi:10.1371/journal.pone.0027970 · Cited by 240
“In addition to mechanisms leading to AR activation in CRPC that require ligand, recent evidence points to the existence of alternatively spliced forms of AR mRNAs that encode receptors devoid of the LBD, but retaining the ability to engage transcriptional machinery and promote the regulation of PLoS ONE | www.plosone.…”
BackgroundInfluentialSelf-citationTargeting the androgen receptor: improving outcomes for castration-resistant prostate cancer
Scher, H. I., Buchanan, G., Gerald, W., Butler, L. M., & Tilley, W. D. (2004) · Endocrine-Related Cancer · doi:10.1677/erc.1.00525 · Cited by 240
Green tea polyphenol EGCG blunts androgen receptor function in prostate cancer
Siddiqui, I. A., Asim, M., Hafeez, B. B., Adhami, V. M., Tarapore, R. S., & Mukhtar, H. (2011) · The FASEB Journal · doi:10.1096/fj.10-167924 · Cited by 234
Role of DAB2IP in modulating epithelial-to-mesenchymal transition and prostate cancer metastasis
Xie, D., Gore, C., Liu, J., Pong, R.-C., Mason, R., Hao, G., Long, M., Kabbani, W., Yu, L., Zhang, H., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0908133107 · Cited by 237
“In addition, we also employed another PCamodel (i.e., LAPC4) expressing androgen receptor (AR) and prostate-specific antigen (PSA) (32) to examine the effect of DAB2IP on cancermetastasis.”
Hormonal Control of Androgen Receptor Function through SIRT1
Fu, M., Liu, M., Sauve, A. A., Jiao, X., Zhang, X., Wu, X., Powell, M. J., Yang, T., Gu, W., Avantaggiati, M. L., et al. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.00289-06 · Cited by 235
“cancer pathogenesis and progression (11).”
Interferon-Inducible Ubiquitin E2, Ubc8, Is a Conjugating Enzyme for Protein ISGylation
Kim, K. I., Giannakopoulos, N. V., Virgin, H. W., & Zhang, D.-E. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.21.9592-9600.2004 · Cited by 233
“To construct MSCV-UbcH8 short hairpin RNA (shRNA), hairpin structured UbcH8 small interfering RNA (siRNA) was amplified with U6 promoter by PCR with primers 5-TTTGGATCCCAAGGTCGGGCAGGAAG AGGGCCTATTTCC-3 and 5-TTTGAATTCAAAAAGCCTTGCACCAAG ACTTGCTCTCTTGAAGCAAGTCTTGGTGCAAGGCTTGGTGTTTCGTC CTTTCCACAAGATATATAA-3 ( 1 ).”
MethodFoxA1 Specifies Unique Androgen and Glucocorticoid Receptor Binding Events in Prostate Cancer Cells
Sahu, B., Laakso, M., Pihlajamaa, P., Ovaska, K., Sinielnikov, I., Hautaniemi, S., & Jänne, O. A. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2350 · Cited by 232
“Cancer Res; 73(5) March 1, 2013 Cancer Research OF6”
BackgroundInfluentialInfluence of Sex Hormones on Cancer Progression
Folkerd, E. J., & Dowsett, M. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.4290 · Cited by 229
Unni, E., Sun, S., Nan, B., McPhaul, M. J., Cheskis, B., Mancini, M. A., & Marcelli, M. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1121 · Cited by 229
“AI CaP may involve a mutated AR (32), ligand-independent AR activation (33, 34), altered expression of a variety of coactivators (35), increased AR expression (36), or intraprostatic levels of androgens that retain the ability to activate AR (37).”
BackgroundWaltering, K. K., Helenius, M. A., Sahu, B., Manni, V., Linja, M. J., Jänne, O. A., & Visakorpi, T. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0919 · Cited by 228
“Several microarray studies have addressed androgen regulation of gene expression in LNCaP cells (20, 29, 30).”
BackgroundInfluentialDillard, P. R., Lin, M.-F., & Khan, S. A. (2008) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2008.08.013 · Cited by 225
Rocchi, P., Beraldi, E., Ettinger, S., Fazli, L., Vessella, R. L., Nelson, C., & Gleave, M. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1840 · Cited by 224
Self-citationNishiyama, T., Hashimoto, Y., & Takahashi, K. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0913 · Cited by 223
“Increased levels of androgen receptor confer resistance to antiandrogens by amplifying signal output from low levels of residual ligand and by altering the normal response to antagonists (23).”
BackgroundMehrian-Shai, R., Chen, C. D., Shi, T., Horvath, S., Nelson, S. F., Reichardt, J. K. V., & Sawyers, C. L. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0609139104 · Cited by 225
Self-citationAndrogen-regulated miR-32 targets BTG2 and is overexpressed in castration-resistant prostate cancer
Jalava, S. E., Urbanucci, A., Latonen, L., Waltering, K. K., Sahu, B., Jänne, O. A., Seppälä, J., Lähdesmäki, H., Tammela, T. L. J., & Visakorpi, T. (2012) · Oncogene · doi:10.1038/onc.2011.624 · Cited by 223
“Despite the low levels of androgens during castration, the AR signaling pathway seems to still be active (Chen et al., 2004; Attard et al., 2008).”
BackgroundStructural basis for the nuclear import of the human androgen receptor
Cutress, M. L., Whitaker, H. C., Mills, I. G., Stewart, M., & Neal, D. E. (2008) · Journal of Cell Science · doi:10.1242/jcs.022103 · Cited by 223
“Furthermore, modest increases in AR protein levels play a crucial role in the development of hormone refractory or hormone-independent prostate cancer (Chen et al., 2004).”
BackgroundRyan, C. J., Shah, S., Efstathiou, E., Smith, M. R., Taplin, M.-E., Bubley, G. J., Logothetis, C. J., Kheoh, T., Kilian, C., Haqq, C. M., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0815 · Cited by 219
PTEN and GSK3β: key regulators of progression to androgen-independent prostate cancer
Mulholland, D. J., Dedhar, S., Wu, H., & Nelson, C. C. (2006) · Oncogene · doi:10.1038/sj.onc.1209020 · Cited by 216
“Finally, studies facilitating hammerhead ribozyme (Zegarra-Moro et al., 2002) or RNAi knockdown of AR (Chen et al., 2004a) indicate that AR may be necessary for proliferation in AI cell lines and xenograft models, respectively.”
BackgroundInfluentialCYP17 inhibitors for prostate cancer therapy
Vasaitis, T. S., Bruno, R. D., & Njar, V. C. O. (2011) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2010.11.005 · Cited by 215
JAK-STAT signaling in cancer: From cytokines to non-coding genome
Pencik, J., Pham, H. T. T., Schmoellerl, J., Javaheri, T., Schlederer, M., Culig, Z., Merkel, O., Moriggl, R., Grebien, F., & Kenner, L. (2016) · Cytokine · doi:10.1016/j.cyto.2016.06.017 · Cited by 215
“Since PCa development is initially dependent on androgens, therapies for advanced PCa usually involve the reduction of androgens or blocking the ligand-binding site of the androgen receptor (AR) [34].”
BackgroundAcute lymphoblastic leukaemia: a model for the pharmacogenomics of cancer therapy
Cheok, M. H., & Evans, W. E. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1800 · Cited by 217
“These promising findings in ALL are fueling the application of similar technologies to many solid tumours in children and adult”
BackgroundAndrogen Receptor Function and Androgen Receptor–Targeted Therapies in Breast Cancer: A Review
Kono, M., Fujii, T., Lim, B., Karuturi, M. S., Tripathy, D., & Ueno, N. T. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.4975 · Cited by 215
“However, acquiredmutations in the ligand-bindingdomainofARor an increase in AR protein concentration causes resistance to bicalutamide.(36) Enzalutamide, a second-generation AR antagonist, inhibits nuclear translocation, chromatin binding, and interactionswith AR coregulators (Figure2).”
BackgroundTargeting the MLL complex in castration-resistant prostate cancer
Malik, R., Khan, A. P., Asangani, I. A., Cieślik, M., Prensner, J. R., Wang, X., Iyer, M. K., Jiang, X., Borkin, D., Escara-Wilke, J., et al. (2015) · Nature Medicine · doi:10.1038/nm.3830 · Cited by 210
Castration-Resistant Prostate Cancer: Locking Up the Molecular Escape Routes
Attar, R. M., Takimoto, C. H., & Gottardis, M. M. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1171 · Cited by 212
“Preclinically, the overexpression of AR has been shown to be involved in the progression to CRPC (12).”
Sircar, K., Yoshimoto, M., Monzon, F. A., Koumakpayi, I. H., Katz, R. L., Khanna, A., Alvarez, K., Chen, G., Darnel, A. D., Aprikian, A. G., et al. (2009) · The Journal of Pathology · doi:10.1002/path.2559 · Cited by 208
“Indeed, upregulation of AR mRNA and protein is now thought to be a principal pathway for the development of the castrate-resistant or hormone refractory state [32].”
BackgroundAttard, G., Belldegrun, A. S., & De Bono, J. S. (2005) · BJU International · doi:10.1111/j.1464-410x.2005.05821.x · Cited by 207
Steinkamp, M. P., O'Mahony, O. A., Brogley, M., Rehman, H., LaPensee, E. W., Dhanasekaran, S., Hofer, M. D., Kuefer, R., Chinnaiyan, A., Rubin, M. A., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3605 · Cited by 210
“Increased AR levels may enhance response to low ligand concentrations, increase ligand-independent activation, or promote agonism of antiandrogens (46).”
Androgens regulate prostate cancer cell growth via an AMPK-PGC-1α-mediated metabolic switch
Tennakoon, J. B., Shi, Y., Han, J. J., Tsouko, E., White, M. A., Burns, A. R., Zhang, A., Xia, X., Ilkayeva, O. R., Xin, L., et al. (2014) · Oncogene · doi:10.1038/onc.2013.463 · Cited by 205
Mechanisms mediating androgen receptor reactivation after castration
Yuan, X., & Balk, S. P. (2009) · Urologic Oncology: Seminars and Original Investigations · doi:10.1016/j.urolonc.2008.03.021 · Cited by 204
“Increased AR expression may enhance any weak residual AR activity that remains after castration, and can enhance growth of a PCa cell line in castrated mice [17].”
Zong, Y., Xin, L., Goldstein, A. S., Lawson, D. A., Teitell, M. A., & Witte, O. N. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0905931106 · Cited by 203
“AR is commonly mutated or amplified in human PCa (3, 35), and the AR pathway is the most extensively studied pathway in PCa because of its role in late-stage hormone-refractory PCa.”
BackgroundVerras, M., Lee, J., Xue, H., Li, T.-H., Wang, Y., & Sun, Z. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3552 · Cited by 203
“AR expression has been observed in most androgen-insensitive prostate cancer cells (41).”
BackgroundAndrogen receptor phosphorylation and stabilization in prostate cancer by cyclin-dependent kinase 1
Chen, S., Xu, Y., Yuan, X., Bubley, G. J., & Balk, S. P. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0604193103 · Cited by 204
Copper Signaling Axis as a Target for Prostate Cancer Therapeutics
Safi, R., Nelson, E. R., Chitneni, S. K., Franz, K. J., George, D. J., Zalutsky, M. R., & McDonnell, D. P. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3527 · Cited by 201
“This finding is significant as AR expression has been found to be consistently upregulated during tumor progression, and that a 2- to 3-fold increase in ARprotein levels is sufficient to facilitate the transition of prostate cancer cells from a hormone-sensitive to a hormone-refractory state in experimental animal mod…”
Memarzadeh, S., Xin, L., Mulholland, D. J., Mansukhani, A., Wu, H., Teitell, M. A., & Witte, O. N. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.11.002 · Cited by 201
“Amplification of the AR gene has been reported in up to 30% of human prostate cancers and is thought to be an important mechanism for formation of androgen independence (Chen et al., 2004; Feldman and Feldman, 2001).”
BackgroundTamura, K., Furihata, M., Tsunoda, T., Ashida, S., Takata, R., Obara, W., Yoshioka, H., Daigo, Y., Nasu, Y., Kumon, H., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4040 · Cited by 206
“Several reports suggested that even under low level of circulating testicular androgen, HRPCs still maintain some level of dependency to the AR pathway (10, 11, 26, 27) and our data also support this concept.”
ResultClark, E. L., Coulson, A., Dalgliesh, C., Rajan, P., Nicol, S. M., Fleming, S., Heer, R., Gaughan, L., Leung, H. Y., Elliott, D. J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0932 · Cited by 201
“A suggested mechanism for maintenance of a functionally active AR is aberrant expression of AR cofactors leading to increased AR sensitivity or promiscuous activation of AR by other steroid hormones (4, 5).”
Role of SRC-1 in the Promotion of Prostate Cancer Cell Growth and Tumor Progression
Agoulnik, I. U., Vaid, A., Bingman, W. E., Erdeme, H., Frolov, A., Smith, C. L., Ayala, G., Ittmann, M. M., & Weigel, N. L. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3541 · Cited by 202
“There is evidence that some prostate tumors that grow in the absence of normal circulating levels of androgens remain androgen receptor dependent (4, 20); alterations in androgen receptor and/or cofactor expression or cellular signaling may allow androgen receptor to function under these conditions (4, 7, 8, 21, 22).”
BackgroundEvolution of androgen receptor targeted therapy for advanced prostate cancer
Wong, Y. N. S., Ferraldeschi, R., Attard, G., & de Bono, J. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.72 · Cited by 197
Buttigliero, C., Tucci, M., Bertaglia, V., Vignani, F., Bironzo, P., Di Maio, M., & Scagliotti, G. V. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.08.002 · Cited by 193
“In the 1990s dedicated studies on AR in CRPC revealed escape mechanisms from androgen blockade through either mutation or amplification of AR [14].”
Li, Y., Hwang, T. H., Oseth, L. A., Hauge, A., Vessella, R. L., Schmechel, S. C., Hirsch, B., Beckman, K. B., Silverstein, K. A., & Dehm, S. M. (2012) · Oncogene · doi:10.1038/onc.2011.637 · Cited by 202
“…mind, it is also important to note that the LuCaP 86.2 xenograft tissue evaluated in this study was propagated in an intact male mouse, and MLPA data reflected an approximate 50/50 mixture of cells with either one intact AR gene copy or one AR gene copy with a 8,579bp deletion of exons 5, 6, and 7.”
InfluentialSelf-citationInhibition of the Androgen Receptor as a Novel Mechanism of Taxol Chemotherapy in Prostate Cancer
Gan, L., Chen, S., Wang, Y., Watahiki, A., Bohrer, L., Sun, Z., Wang, Y., & Huang, H. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1504 · Cited by 197
Lei, Q., Jiao, J., Xin, L., Chang, C.-J., Wang, S., Gao, J., Gleave, M. E., Witte, O. N., Liu, X., & Wu, H. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.03.031 · Cited by 198
“1 knockout mice (Abdulkadir et al., 2002; Kim et al., 2002a) and prostate cancer development in Pten null model (Wang et al., 2003), similar to what has been concluded from AR transgenic animals (Stanbrough et al., 2001) and human prostate cancer studies (Chen et al., 2004).”
ResultAndrogen Receptor Signaling in the Development of Castration-Resistant Prostate Cancer
Feng, Q., & He, B. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00858 · Cited by 193
Ferraldeschi, R., Welti, J., Luo, J., Attard, G., & de Bono, J. S. (2015) · Oncogene · doi:10.1038/onc.2014.115 · Cited by 192
Androgen receptor signaling in castration-resistant prostate cancer: a lesson in persistence
Coutinho, I., Day, T. K., Tilley, W. D., & Selth, L. A. (2016) · Endocrine-Related Cancer · doi:10.1530/erc-16-0422 · Cited by 194
Cao, B., Qi, Y., Zhang, G., Xu, D., Zhan, Y., Alvarez, X., Guo, Z., Fu, X., Plymate, S. R., Sartor, O., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.1802 · Cited by 194
“For example, overexpression of the full-length AR (AR-FL) was shown to convert prostate cancer growth from a castration-sensitive to a castrationresistant stage [3].”
BackgroundTeply, B. A., Wang, H., Luber, B., Sullivan, R., Rifkind, I., Bruns, A., Spitz, A., DeCarli, M., Sinibaldi, V., Pratz, C. F., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30906-3 · Cited by 193
Mutation of the androgen receptor causes oncogenic transformation of the prostate.
Han, G., Buchanan, G., Ittmann, M., Harris, J. M., Yu, X., DeMayo, F. J., Tilley, W., & Greenberg, N. M. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408925102 · Cited by 192
Comparative expression pathway analysis of human and canine mammary tumors
Uva, P., Aurisicchio, L., Watters, J., Loboda, A., Kulkarni, A., Castle, J., Palombo, F., Viti, V., Mesiti, G., Zappulli, V., et al. (2009) · BMC Genomics · doi:10.1186/1471-2164-10-135 · Cited by 193
“The signatures composing the compendium were defined in independent studies using different methodologies and cancer models, including human primary breast tumors, tumors from transgenic mice, and in vitro cell lines (Table 1) [37-41,64-73].”
MethodNF-κB Regulates Androgen Receptor Expression and Prostate Cancer Growth
Zhang, L., Altuwaijri, S., Deng, F., Chen, L., Lal, P., Bhanot, U. K., Korets, R., Wenske, S., Lilja, H. G., Chang, C., et al. (2009) · The American Journal of Pathology · doi:10.2353/ajpath.2009.080727 · Cited by 191
Kang, Z., Jänne, O. A., & Palvimo, J. J. (2004) · Molecular Endocrinology · doi:10.1210/me.2004-0245 · Cited by 193
“This antagonist-to-agonist conversion in CDX function was linked to altered recruitment of coactivators and corepressors onto the PSA and KLK2 promoters (52).”
Anoikis and EMT: Lethal "Liaisons" during Cancer Progression
Cao, Z., Livas, T., & Kyprianou, N. (2016) · Critical Reviews™ in Oncogenesis · doi:10.1615/critrevoncog.2016016955 · Cited by 193
Fan, W., Yanase, T., Morinaga, H., Okabe, T., Nomura, M., Daitoku, H., Fukamizu, A., Kato, S., Takayanagi, R., & Nawata, H. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m610447200 · Cited by 188
Nickols, N. G., & Dervan, P. B. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0704217104 · Cited by 189
Kong, L., Yuan, Q., Zhu, H., Li, Y., Guo, Q., Wang, Q., Bi, X., & Gao, X. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.05.032 · Cited by 187
Androgen receptor (AR) aberrations in castration-resistant prostate cancer
Waltering, K. K., Urbanucci, A., & Visakorpi, T. (2012) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2011.12.019 · Cited by 189
“Overexpression of AR has experimentally been shown to convert the androgen-sensitive growth to androgen independent one (Chen et al., 2004) and hypersensitize AR signaling pathway (Waltering et al.”
BackgroundMolecular events in neuroendocrine prostate cancer development
Wang, Y., Wang, Y., Ci, X., Choi, S. Y. C., Crea, F., Lin, D., & Wang, Y. (2021) · Nature Reviews Urology · doi:10.1038/s41585-021-00490-0 · Cited by 182
Deep whole-genome ctDNA chronology of treatment-resistant prostate cancer
Herberts, C., Annala, M., Sipola, J., Ng, S. W. S., Chen, X. E., Nurminen, A., Korhonen, O. V., Munzur, A. D., Beja, K., Schönlau, E., et al. (2022) · Nature · doi:10.1038/s41586-022-04975-9 · Cited by 185
Nadiminty, N., Tummala, R., Lou, W., Zhu, Y., Zhang, J., Chen, X., deVere White, R. W., Kung, H.-J., Evans, C. P., & Gao, A. C. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.278705 · Cited by 186
“High levels of AR expression also convert AR antagonists like bicalutamide and flutamide into agonists and confer promiscuity to ligands like estrogens (33).”
BackgroundNew Strategies in Metastatic Prostate Cancer: Targeting the Androgen Receptor Signaling Pathway
Attard, G., Richards, J., & de Bono, J. S. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0567 · Cited by 183
“undergo a number of genomic and expression changes involving the AR and its associated coactivators and corepressors that could allow continued activation of the AR signaling axis by castrate levels of androgens (11).”
BackgroundMolecular Alterations in Primary Prostate Cancer after Androgen Ablation Therapy
Best, C. J. M., Gillespie, J. W., Yi, Y., Chandramouli, G. V. R., Perlmutter, M. A., Gathright, Y., Erickson, H. S., Georgevich, L., Tangrea, M. A., Duray, P. H., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0585 · Cited by 186
“2), and recent studies using prostate cancer models have shed additional light on the process (3), our understanding of the disease in patients remains incomplete at the molecular level, and the key genes involved are still largely unknown.”
BackgroundSabnis, A. J., & Bivona, T. G. (2019) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2018.12.009 · Cited by 189
Bonkhoff, H., & Berges, R. (2009) · European Urology · doi:10.1016/j.eururo.2008.10.035 · Cited by 185
“This hypersensitive pathway has been recognised as one of the most important mechanisms involved in the development of castration-resistant disease [35].”
BackgroundJin, R. J., Lho, Y., Connelly, L., Wang, Y., Yu, X., Saint Jean, L., Case, T. C., Ellwood-Yen, K., Sawyers, C. L., Bhowmick, N. A., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0107 · Cited by 182
Self-citationAndrogen action and metabolism in prostate cancer
Green, S. M., Mostaghel, E. A., & Nelson, P. S. (2012) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2011.09.046 · Cited by 181
“Prostate cancer growth in castrate animal models is characterized by AR overexpression and remains ligand sensitive (Chen et al., 2004).”
BackgroundWelsbie, D. S., Xu, J., Chen, Y., Borsu, L., Scher, H. I., Rosen, N., & Sawyers, C. L. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2216 · Cited by 182
Self-citationSerial blood-based analysis of AR-V7 in men with advanced prostate cancer
Nakazawa, M., Lu, C., Chen, Y., Paller, C. J., Carducci, M. A., Eisenberger, M. A., Luo, J., & Antonarakis, E. S. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv282 · Cited by 178
“Several mechanisms of castration resistance have been identified, many of which contribute to sustained AR signaling: production of adrenal and intratumoral androgens [2–4], AR amplification or overexpression [5, 6], AR activation through alternative pathways [7, 8], nontraditional ligand synthesis pathways [9, 10], a…”
BackgroundAdvances in Prostate Cancer Chemotherapy: A New Era Begins
Pienta, K. J., & Smith, D. C. (2005) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.55.5.300 · Cited by 185
Androgen receptor outwits prostate cancer drugs
Isaacs, J. T., & Isaacs, W. B. (2004) · Nature Medicine · doi:10.1038/nm0104-26 · Cited by 182
Vawter, M. P., Tomita, H., Meng, F., Bolstad, B., Li, J., Evans, S., Choudary, P., Atz, M., Shao, L., Neal, C., et al. (2006) · Molecular Psychiatry · doi:10.1038/sj.mp.4001830 · Cited by 188
Li, Z. G., Mathew, P., Yang, J., Starbuck, M. W., Zurita, A. J., Liu, J., Sikes, C., Multani, A. S., Efstathiou, E., Lopez, A., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci33093 · Cited by 180
Yoshida, T., Kinoshita, H., Segawa, T., Nakamura, E., Inoue, T., Shimizu, Y., Kamoto, T., & Ogawa, O. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0817 · Cited by 178
“Recent studies show that the androgen receptor (AR) signaling continues to influence prostate cancer growth even after androgen ablation (1).”
Emodin Down-Regulates Androgen Receptor and Inhibits Prostate Cancer Cell Growth
Cha, T.-L., Qiu, L., Chen, C.-T., Wen, Y., & Hung, M.-C. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3250 · Cited by 178
“A recent study showed that overexpression of AR in hormonerefractory xenograft model is consistent with observations in human clinical specimens, and overexpression of AR promotes the transition of hormone-dependent xenograft into a hormoneindependent xenograft ( 47 , 48).”
Self-citationAndrogen-Induced Differentiation and Tumorigenicity of Human Prostate Epithelial Cells
Berger, R., Febbo, P. G., Majumder, P. K., Zhao, J. J., Mukherjee, S., Signoretti, S., Campbell, K. T., Sellers, W. R., Roberts, T. M., Loda, M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2938 · Cited by 177
“Consistent with these observations, a recent study showed that increases in AR mRNA and protein levels was necessary and sufficient to convert prostate cancer cells from a hormone-sensitive to a hormone-refractory state and that these effects required a functional ligand-binding domain (3).”
ResultLiao, X., Tang, S., Thrasher, J. B., Griebling, T. L., & Li, B. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-04-0313 · Cited by 176
“Consistent with two recent reports showing a reduced cell proliferation after AR protein was knocked down via the RNAi approach (8, 39), we also found that cell growth was largely reduced after transfection of LAPC-4 cells with either AR siRNA 8 or a pooled AR siRNA mixture (Fig.”
BackgroundMethodResultInfluentialStress Kinase Signaling Regulates Androgen Receptor Phosphorylation, Transcription, and Localization
Gioeli, D., Black, B. E., Gordon, V., Spencer, A., Kesler, C. T., Eblen, S. T., Paschal, B. M., & Weber, M. J. (2006) · Molecular Endocrinology · doi:10.1210/me.2005-0351 · Cited by 175
Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer
Wadosky, K. M., & Koochekpour, S. (2016) · Oncotarget · doi:10.18632/oncotarget.10901 · Cited by 174
“miR-34a has been shown to specifically downregulate expression of AR [165], suggesting that loss of miR-34a could contribute to increases in AR expression observed in human CR-PCa tumors, cell lines, and xenograft models described above [91, 92].”
BackgroundInfluentialDirect, Androgen Receptor-Mediated Regulation of the FKBP5 Gene via a Distal Enhancer Element
Magee, J. A., Chang, L.-W., Stormo, G. D., & Milbrandt, J. (2006) · Endocrinology · doi:10.1210/en.2005-1001 · Cited by 174
Henzler, C., Li, Y., Yang, R., McBride, T., Ho, Y., Sprenger, C., Liu, G., Coleman, I., Lakely, B., Li, R., et al. (2016) · Nature Communications · doi:10.1038/ncomms13668 · Cited by 173
“AR amplification or mutation has been shown to promote resistance to first-line ADT by causing aberrant AR responses to antiandrogens, castrate levels of androgens and alternative steroids 3,32–34 .”
Interleukin-6: A multifunctional targetable cytokine in human prostate cancer
Culig, Z., & Puhr, M. (2012) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2011.05.033 · Cited by 170
“AR has been identified as a target for therapy in human prostate cancer since it is overexpressed in many therapy-resistant tumours and its inhibition may contribute to delayed tumour progression (Zegarra-Moro et al., 2002; Chen et al., 2004; Andersen et al., 2010; Siddiqui et al., 2011).”
Metadata
- Authors
- Chen, C. D., Welsbie, D. S., Tran, C., Baek, S. H., Chen, R., Vessella, R., Rosenfeld, M. G., & Sawyers, C. L.
- Affiliations
- University of California, Los Angeles (US)
- Howard Hughes Medical Institute (US)
- University of Washington (US)
- Corresponding author
- Sawyers, Charles L
- Venue
- Nature Medicine
- Published
- 2003-12-21
- Volume
- 10
- Issue
- 1
- Pages
- 33-39
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2003955264
- Cited by
- 2,278
- References
- 50
- Citations by year
- 2026: 21 · 2025: 40 · 2024: 40 · 2023: 72 · 2022: 59 · 2021: 86 · 2020: 68 · 2019: 82 · 2018: 99 · 2017: 110 · 2016: 106 · 2015: 119 · 2014: 128 · 2013: 156 · 2012: 155
- FWCI
- 69.78
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Keywords
- prostate cancer, antiandrogen resistance, androgen receptor, castration-resistant prostate cancer, androgen receptor ligand-binding domain, coactivator recruitment, corepressor recruitment, androgen receptor target genes
- MeSH terms
- Androgen Antagonists, Base Sequence, Humans, Male, Prostatic Neoplasms, Receptors, Androgen, DNA Primers, Disease Progression, Antineoplastic Agents, Hormonal, Drug Resistance, Neoplasm
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.